<DOC>
	<DOC>NCT00782041</DOC>
	<brief_summary>Primary: - To assess the overall response rate of oxaliplatin in patients with bidimensionally measurable disease at baseline. Secondary: - To assess the safety and tolerability of oxaliplatin - To assess time to progression and overall survival.</brief_summary>
	<brief_title>Patients Who Have Failed First Line Treatment for Locally Advanced and/or Metastatic Cervical Cancer</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Uterine Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Have Locally advanced/metastatic squamous or adenocarcinoma of the cervix Prior therapy with cisplatin allowed Firstline treatment may have been surgery,radiotherapy or chemotherapy either as a single agent or multimodality therapy Must have measurable disease Histologically Proven Carcinoma of the cervix ECOG PS ≤2 No other serious concomitant illness Fully recovered from any prior therapy Lab: ANC &gt;1500 mm³, Platelets &gt; 100000 mm³, Creatinine ≤ 1.5 x Normal value, Bilirubin ≤ 1.5 x Normal value, SGPT (ALT) ≤ 2.5 x Normal value Known allergy to one of the study drugs Peripheral neuropathy &gt; grade2 The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>